Literature DB >> 819625

Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy.

M Matthew, A M Harris.   

Abstract

beta-Lactamases (EC. 3.5.2.6) can be directly compared by analytical isoelectric focusing. Using this technique, 242 strains from five Gram-positive and 16 Gram-negative genera were examined. A preparation of each strain focused as a single group of bands which did not match the pattern of any R factor-associated beta-lactamase. None of the strains was known to carry an R factor and resistance transfer experiments were unsuccessful. The enzymes studied were therefore thought to be chromosomally mediated. The isoelectric points ranged from 3.9 to 8.7 and were not related to the substrate profiles or other biochemical properties. The chromosomal beta-lactamases appeared to be specific for genus, species and sub-species, and strains that produced identical beta-lactamases had identical bacterial characteristics. Correlation of bacteriological differences with differences in beta-lactamase patterns is discussed with particular reference to strains of Escherichia coli and Klebsiella spp. Since beta-lactamases may be universally produced by bacteria, separation of the enzymes by analytical isoelectric focusing could be used in bacterial taxonomy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 819625     DOI: 10.1099/00221287-94-1-55

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  54 in total

1.  Diversity of SHV and TEM beta-lactamases in Klebsiella pneumoniae: gene evolution in Northern Taiwan and two novel beta-lactamases, SHV-25 and SHV-26.

Authors:  F Y Chang; L K Siu; C P Fung; M H Huang; M Ho
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.

Authors:  A M Queenan; S Jenkins; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  High-level expression of ampC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment.

Authors:  L K Siu; Po-Liang Lu; J-Y Chen; F M Lin; Shan-Chwen Chang
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

4.  Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii.

Authors:  G Bou; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

5.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum beta-lactamase.

Authors:  Kerry J Welsh; Miriam Barlow; Fred C Tenover; James W Biddle; J Kamile Rasheed; Leigh Ann Clark; John E McGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Characterization of four beta-lactamases produced by Staphylococcus aureus.

Authors:  D J Zygmunt; C W Stratton; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

8.  Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa.

Authors:  M L Gates; C C Sanders; R V Goering; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Beta-lactamase types and beta-lactam resistance of Escherichia coli strains with chromosomally mediated ampicillin resistance.

Authors:  R Marre; S Aleksic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

10.  What do beta-lactamases mean for clinical efficacy?

Authors:  H C Neu
Journal:  Infection       Date:  1983       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.